









市场行情
/
股票
/
nasdaq-tcrx
/

TScan Therapeutics Inc

TCRX

0.896USD

-0.035-3.79%

收盘 12/19, 16:00（美东）报价延迟15分钟

50.83M总市值

亏损市盈率 TTM



TScan Therapeutics Inc

0.896

-0.035-3.79%

概览公司财务分析

概览

公司

财务

分析

关于 TScan Therapeutics Inc 公司

TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.

TScan Therapeutics Inc简介



公司代码TCRX

公司名称TScan Therapeutics Inc

上市日期Jul 16, 2021

CEOMacbeath (Gavin)

员工数量194

证券类型Ordinary Share

年结日Jul 16

公司地址830 Winter Street

城市WALTHAM

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02451

电话18573999500

网址https://www.tscan.com

公司代码TCRX

上市日期Jul 16, 2021

CEOMacbeath (Gavin)

TScan Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Zoran Zdraveski, J.D., Ph.D.

Chief Legal and Strategy Officer, Secretary

84.61K

+1694.13%

Mr. Gavin Macbeath, Ph.D.

Chief Executive Officer, Director

49.77K

Mr. Garry A. Nicholson

Independent Director

Mr. R. Keith Woods

Independent Director

Dr. Stephen R. Biggar, M.D., Ph.D.

Independent Non-Executive Chairman of the Board

Jason A. Amello ,

Chief Financial Officer, Treasurer

Dr. Chrystal U. Louis

Chief Medical Officer

Ms. Katina Dorton

Independent Director

Dr. Barbara J. Klencke, M.D.

Independent Director

Dr. Gabriela Gruia, M.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Zoran Zdraveski, J.D., Ph.D.

Chief Legal and Strategy Officer, Secretary

84.61K

+1694.13%

Mr. Gavin Macbeath, Ph.D.

Chief Executive Officer, Director

49.77K

Mr. Garry A. Nicholson

Independent Director

Mr. R. Keith Woods

Independent Director

Dr. Stephen R. Biggar, M.D., Ph.D.

Independent Non-Executive Chairman of the Board

Jason A. Amello ,

Chief Financial Officer, Treasurer

收入明细

FY2025Q2

FY2025Q1

FY2024

FY2023

FY2022

FY2021

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

3.08M

0.00%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 12月4日周四

持股股东

股东类型

持股股东

占比

Lynx1 Capital Advisors LLC

14.97%

BVF Partners L.P.

9.96%

K2 HealthVentures LLC

6.87%

Simplify Asset Management Inc

5.41%

Baker Bros. Advisors LP

5.31%

其他

57.48%

持股股东

占比

Lynx1 Capital Advisors LLC

14.97%

BVF Partners L.P.

9.96%

K2 HealthVentures LLC

6.87%

Simplify Asset Management Inc

5.41%

Baker Bros. Advisors LP

5.31%

其他

57.48%

股东类型

持股股东

占比

Investment Advisor

29.70%

Hedge Fund

21.44%

Venture Capital

11.33%

Investment Advisor/Hedge Fund

7.88%

Research Firm

2.72%

Individual Investor

0.39%

Bank and Trust

0.27%

其他

26.27%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

198

42.06M

80.16%

-7.95M

2025Q2

192

48.33M

92.38%

-952.90K

2025Q1

198

46.53M

88.95%

-3.07M

2024Q4

184

47.92M

91.75%

+202.11K

2024Q3

172

45.30M

92.65%

-3.14M

2024Q2

147

48.79M

100.07%

+12.56M

2024Q1

110

39.09M

88.67%

+3.45M

2023Q4

36.63M

84.04%

+3.23M

2023Q3

33.69M

84.61%

-2.13M

2023Q2

32.77M

82.58%

-787.78K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Lynx1 Capital Advisors LLC

7.86M

14.97%

-88.79K

-1.12%

Jun 30, 2025

BVF Partners L.P.

5.23M

9.96%

+336.60K

+6.88%

Jun 30, 2025

K2 HealthVentures LLC

3.60M

6.87%

+2.90M

+414.67%

Dec 31, 2024

Simplify Asset Management Inc

1.05M

Jun 30, 2025

Baker Bros. Advisors LP

2.78M

5.31%

Jun 30, 2025

The Vanguard Group, Inc.

2.15M

4.1%

-207.37K

-8.80%

Jun 30, 2025

abrdn Inc.

891.45K

1.7%

Jun 30, 2025

BlackRock Financial Management, Inc.

1.32M

2.51%

-529.55K

-28.71%

Jun 30, 2025

Bessemer Venture Partners

1.25M

2.37%

Jun 30, 2025

Alphabet, Inc.

1.08M

2.05%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Simplify Propel Opportunities ETF

1.72%

iShares Health Innovation Active ETF

0.13%

iShares Micro-Cap ETF

0.02%

iShares Biotechnology ETF

0.01%

Invesco Nasdaq Biotechnology ETF

0.01%

ProShares Ultra Nasdaq Biotechnology

0.01%

Invesco Dorsey Wright SmallCap Momentum ETF

DFA Dimensional US Sustainability Core 1 ETF

DFA Dimensional US Core Equity Market ETF

iShares Russell 3000 ETF

Simplify Propel Opportunities ETF

占比1.72%

iShares Health Innovation Active ETF

占比0.13%

iShares Micro-Cap ETF

占比0.02%

iShares Biotechnology ETF

占比0.01%

Invesco Nasdaq Biotechnology ETF

占比0.01%

ProShares Ultra Nasdaq Biotechnology

占比0.01%

Invesco Dorsey Wright SmallCap Momentum ETF

占比0%

DFA Dimensional US Sustainability Core 1 ETF

占比0%

DFA Dimensional US Core Equity Market ETF

占比0%

iShares Russell 3000 ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

TScan Therapeutics Inc的前五大股东是谁？



TScan Therapeutics Inc 的前五大股东如下：
Lynx1 Capital Advisors LLC持有股份：7.86M，占总股份比例：14.97%。
BVF Partners L.P.持有股份：5.23M，占总股份比例：9.96%。
K2 HealthVentures LLC持有股份：3.60M，占总股份比例：6.87%。
Simplify Asset Management Inc持有股份：1.05M，占总股份比例：2.00%。
Baker Bros. Advisors LP持有股份：2.78M，占总股份比例：5.31%。